123 related articles for article (PubMed ID: 25829023)
1. Oral cyclosporine A treatment is feasible after myeloablative conditioning in allogeneic hematopoietic stem cell transplantation.
Nygaard M; Hovgaard D; Schjødt IM; Andersen NS; Vindeløv L; Sengeløv H
J Clin Pharm Ther; 2015 Jun; 40(3):358-61. PubMed ID: 25829023
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of cyclosporine A at a high-peak concentration of twice-daily infusion and oral administration in allogeneic haematopoietic stem cell transplantation.
Inoue Y; Saito T; Ogawa K; Nishio Y; Kosugi S; Suzuki Y; Shibuya Y; Kato M; Takahashi M; Miura I
J Clin Pharm Ther; 2011 Aug; 36(4):518-24. PubMed ID: 21105879
[TBL] [Abstract][Full Text] [Related]
3. Impact of cyclosporine A concentration on acute graft-vs-host disease incidence after haploidentical hematopoietic cell transplantation.
Stocker N; Duléry R; Battipaglia G; Brissot E; Médiavilla C; Sestili S; Paviglianiti A; Ledraa T; Mohty R; Bazarbachi A; Belhocine R; Vekhoff A; Ruggeri A; Mohty M; Malard F
Eur J Haematol; 2019 Jul; 103(1):10-17. PubMed ID: 30958904
[TBL] [Abstract][Full Text] [Related]
4. Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation.
Malard F; Szydlo RM; Brissot E; Chevallier P; Guillaume T; Delaunay J; Ayari S; Dubruille V; Le Gouill S; Mahe B; Gastinne T; Blin N; Saulquin B; Harousseau JL; Moreau P; Mohty M
Biol Blood Marrow Transplant; 2010 Jan; 16(1):28-34. PubMed ID: 20053329
[TBL] [Abstract][Full Text] [Related]
5. Cyclosporine levels > 195 μg/L on day 10 post-transplant was associated with significantly reduced acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Bianchi M; Heim D; Lengerke C; Halter J; Gerull S; Kleber M; Tsakiris DA; Passweg J; Tzankov A; Medinger M
Ann Hematol; 2019 Apr; 98(4):971-977. PubMed ID: 30542943
[TBL] [Abstract][Full Text] [Related]
6. Cyclosporine A (CsA) 2-h concentrations vary between patients without correlation to graft-versus-host disease after allogeneic haematopoietic stem cell transplantation.
Barkholt L; Remberger M; Bodegård H; Ringdén O; Böttiger Y
Bone Marrow Transplant; 2007 Oct; 40(7):683-9. PubMed ID: 17660840
[TBL] [Abstract][Full Text] [Related]
7. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
[TBL] [Abstract][Full Text] [Related]
8. Achievement of target cyclosporine concentrations as a predictor of severe acute graft versus host disease in children undergoing hematopoietic stem cell transplantation and receiving cyclosporine and methotrexate prophylaxis.
Punnett A; Sung L; Price V; Das P; Diezi M; Doyle J; Dupuis LL
Ther Drug Monit; 2007 Dec; 29(6):750-7. PubMed ID: 18043472
[TBL] [Abstract][Full Text] [Related]
9. Effect of cyclophosphamide on serum cyclosporine levels at the conditioning of hematopoietic stem cell transplantation.
Nagamura F; Takahashi T; Takeuchi M; Iseki T; Ooi J; Tomonari A; Uchimaru K; Takahashi S; Tojo A; Tani K; Asano S
Bone Marrow Transplant; 2003 Dec; 32(11):1051-8. PubMed ID: 14625575
[TBL] [Abstract][Full Text] [Related]
10. The safety and efficacy of acute graft-versus-host disease prophylaxis with a higher target blood concentration of cyclosporine around 500 ng/mL.
Machishima T; Kako S; Wada H; Yamasaki R; Ishihara Y; Kawamura K; Sakamoto K; Sato M; Ashizawa M; Terasako K; Kimura S; Kikuchi M; Nakasone H; Kanda J; Yamazaki R; Nishida J; Kanda Y
Clin Transplant; 2013; 27(5):749-56. PubMed ID: 24033855
[TBL] [Abstract][Full Text] [Related]
11. The effect of cyclosporine initiation time on the outcome of matched allogeneic stem-cell transplantation following fludarabine-based conditioning.
Kedmi M; Dray L; Grisariu S; Resnick IB; Stepensky P; Aker M; Or R; Shapira MY
Transpl Int; 2012 Dec; 25(12):1241-7. PubMed ID: 22974004
[TBL] [Abstract][Full Text] [Related]
12. Limited sampling strategies for estimating intravenous and oral cyclosporine area under the curve in pediatric hematopoietic stem cell transplantation.
Sarem S; Nekka F; Barrière O; Bittencourt H; Duval M; Teira P; Haddad E; Théorêt Y; Lapeyraque AL; Litalien C
Ther Drug Monit; 2015 Apr; 37(2):198-205. PubMed ID: 25162214
[TBL] [Abstract][Full Text] [Related]
13. Decreased incidence of acute graft-versus-host disease by continuous infusion of cyclosporine with a higher target blood level.
Oshima K; Kanda Y; Nakasone H; Arai S; Nishimoto N; Sato H; Watanabe T; Hosoya N; Izutsu K; Asai T; Hangaishi A; Motokura T; Chiba S; Kurokawa M
Am J Hematol; 2008 Mar; 83(3):226-32. PubMed ID: 17918253
[TBL] [Abstract][Full Text] [Related]
14. Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis.
Byrne JL; Stainer C; Hyde H; Miflin G; Haynes AP; Bessell EM; Russell NH
Bone Marrow Transplant; 1998 Sep; 22(6):541-5. PubMed ID: 9758340
[TBL] [Abstract][Full Text] [Related]
15. Mycophenolate-based graft versus host disease prophylaxis is not inferior to methotrexate in myeloablative-related donor stem cell transplantation.
Hamad N; Shanavas M; Michelis FV; Uhm J; Gupta V; Seftel M; Kuruvilla J; Lipton JH; Messner HA; Kim DD
Am J Hematol; 2015 May; 90(5):392-9. PubMed ID: 25615933
[TBL] [Abstract][Full Text] [Related]
16. Cyclosporine A trough concentrations are associated with acute GvHD after non-myeloablative allogeneic hematopoietic cell transplantation.
de Kort EA; de Lil HS; Bremmers MEJ; van Groningen LFJ; Blijlevens NMA; Huls G; Brüggemann RJM; van Dorp S; van der Velden WJFM
PLoS One; 2019; 14(3):e0213913. PubMed ID: 30897127
[TBL] [Abstract][Full Text] [Related]
17. Effect of blood cyclosporine concentration on the outcome of hematopoietic stem cell transplantation from an HLA-matched sibling donor.
Kanda Y; Hyo R; Yamashita T; Fujimaki K; Oshima K; Onoda M; Mori T; Sakura T; Tanaka M; Sakai M; Taguchi J; Kurakawa M; Maruta A; Okamoto S; Sakamaki H;
Am J Hematol; 2006 Nov; 81(11):838-44. PubMed ID: 16888784
[TBL] [Abstract][Full Text] [Related]
18. Converting cyclosporine A from intravenous to oral administration in hematopoietic stem cell transplant recipients and the role of azole antifungals.
Atiq F; Hameli E; Broers AEC; Doorduijn JK; Van Gelder T; Andrews LM; Koch BCP; Versmissen J; de Winter BCM
Eur J Clin Pharmacol; 2018 Jun; 74(6):767-773. PubMed ID: 29500599
[TBL] [Abstract][Full Text] [Related]
19. Impact of cyclosporine levels on the development of acute graft versus host disease after reduced intensity conditioning allogeneic stem cell transplantation.
García Cadenas I; Valcarcel D; Martino R; Piñana JL; Barba P; Novelli S; Esquirol A; Garrido A; Saavedra S; Granell M; Moreno C; Briones J; Brunet S; Sierra J
Mediators Inflamm; 2014; 2014():620682. PubMed ID: 24623962
[TBL] [Abstract][Full Text] [Related]
20. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.
Finke J; Bethge WA; Schmoor C; Ottinger HD; Stelljes M; Zander AR; Volin L; Ruutu T; Heim DA; Schwerdtfeger R; Kolbe K; Mayer J; Maertens JA; Linkesch W; Holler E; Koza V; Bornhäuser M; Einsele H; Kolb HJ; Bertz H; Egger M; Grishina O; Socié G;
Lancet Oncol; 2009 Sep; 10(9):855-64. PubMed ID: 19695955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
